372 related articles for article (PubMed ID: 24236104)
21. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of Cystathionine-β-Synthase in Colonic Epithelia Reprograms Metabolism and Promotes Carcinogenesis.
Phillips CM; Zatarain JR; Nicholls ME; Porter C; Widen SG; Thanki K; Johnson P; Jawad MU; Moyer MP; Randall JW; Hellmich JL; Maskey M; Qiu S; Wood TG; Druzhyna N; Szczesny B; Módis K; Szabo C; Chao C; Hellmich MR
Cancer Res; 2017 Nov; 77(21):5741-5754. PubMed ID: 28923859
[TBL] [Abstract][Full Text] [Related]
24. Activation of the reverse transsulfuration pathway through NRF2/CBS confers erastin-induced ferroptosis resistance.
Liu N; Lin X; Huang C
Br J Cancer; 2020 Jan; 122(2):279-292. PubMed ID: 31819185
[TBL] [Abstract][Full Text] [Related]
25. H
Nandi SS; Mishra PK
Sci Rep; 2017 Jun; 7(1):3639. PubMed ID: 28623294
[TBL] [Abstract][Full Text] [Related]
26. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
[TBL] [Abstract][Full Text] [Related]
28. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.
Rodriguez-Aguayo C; Bayraktar E; Ivan C; Aslan B; Mai J; He G; Mangala LS; Jiang D; Nagaraja AS; Ozpolat B; Chavez-Reyes A; Ferrari M; Mitra R; Siddik ZH; Shen H; Yang X; Sood AK; Lopez-Berestein G
EBioMedicine; 2019 Feb; 40():290-304. PubMed ID: 30655206
[TBL] [Abstract][Full Text] [Related]
29. Cystathionine-β-synthase is essential for AKT-induced senescence and suppresses the development of gastric cancers with PI3K/AKT activation.
Zhu H; Chan KT; Huang X; Cerra C; Blake S; Trigos AS; Anderson D; Creek DJ; De Souza DP; Wang X; Fu C; Jana M; Sanij E; Pearson RB; Kang J
Elife; 2022 Jun; 11():. PubMed ID: 35758651
[TBL] [Abstract][Full Text] [Related]
30. Frequent epigenetic silencing of the folate-metabolising gene cystathionine-beta-synthase in gastrointestinal cancer.
Zhao H; Li Q; Wang J; Su X; Ng KM; Qiu T; Shan L; Ling Y; Wang L; Cai J; Ying J
PLoS One; 2012; 7(11):e49683. PubMed ID: 23152928
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of cystathionine-β-synthase inhibition by disulfiram: The role of bis(N,N-diethyldithiocarbamate)-copper(II).
Zuhra K; Panagaki T; Randi EB; Augsburger F; Blondel M; Friocourt G; Herault Y; Szabo C
Biochem Pharmacol; 2020 Dec; 182():114267. PubMed ID: 33035509
[TBL] [Abstract][Full Text] [Related]
32. Emerging roles of cystathionine β-synthase in various forms of cancer.
Ascenção K; Szabo C
Redox Biol; 2022 Jul; 53():102331. PubMed ID: 35618601
[TBL] [Abstract][Full Text] [Related]
33. Cystathionine β-synthase Induces Multidrug Resistance and Metastasis in Hepatocellular Carcinoma.
Wang L; Han H; Liu Y; Zhang X; Shi X; Wang T
Curr Mol Med; 2018; 18(7):496-506. PubMed ID: 30539696
[TBL] [Abstract][Full Text] [Related]
34. Short-term single treatment of chemotherapy results in the enrichment of ovarian cancer stem cell-like cells leading to an increased tumor burden.
Abubaker K; Latifi A; Luwor R; Nazaretian S; Zhu H; Quinn MA; Thompson EW; Findlay JK; Ahmed N
Mol Cancer; 2013 Mar; 12():24. PubMed ID: 23537295
[TBL] [Abstract][Full Text] [Related]
35. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.
Fang F; Munck J; Tang J; Taverna P; Wang Y; Miller DF; Pilrose J; Choy G; Azab M; Pawelczak KS; VanderVere-Carozza P; Wagner M; Lyons J; Matei D; Turchi JJ; Nephew KP
Clin Cancer Res; 2014 Dec; 20(24):6504-16. PubMed ID: 25316809
[TBL] [Abstract][Full Text] [Related]
36. piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in Ovarian Cancer.
Yan Y; Tian D; Zhao B; Li Z; Huang Z; Li K; Chen X; Zhou L; Feng Y; Yang Z
Technol Cancer Res Treat; 2024; 23():15330338241249692. PubMed ID: 38706262
[TBL] [Abstract][Full Text] [Related]
37. Notch3 overexpression as potential therapeutic target in advanced stage chemoresistant ovarian cancer.
Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama S; Otsuki Y; Miyazaki K
Am J Clin Pathol; 2012 Oct; 138(4):535-44. PubMed ID: 23010708
[TBL] [Abstract][Full Text] [Related]
38. TR3 modulates platinum resistance in ovarian cancer.
Wilson AJ; Liu AY; Roland J; Adebayo OB; Fletcher SA; Slaughter JC; Saskowski J; Crispens MA; Jones HW; James S; Fadare O; Khabele D
Cancer Res; 2013 Aug; 73(15):4758-69. PubMed ID: 23720056
[TBL] [Abstract][Full Text] [Related]
39. Galectin-3 regulates chemotherapy sensitivity in epithelial ovarian carcinoma via regulating mitochondrial function.
Wang D; You D; Li L
J Toxicol Sci; 2019; 44(1):47-56. PubMed ID: 30626779
[TBL] [Abstract][Full Text] [Related]
40. A critical role of Oct4A in mediating metastasis and disease-free survival in a mouse model of ovarian cancer.
Samardzija C; Luwor RB; Volchek M; Quinn MA; Findlay JK; Ahmed N
Mol Cancer; 2015 Aug; 14():152. PubMed ID: 26260289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
